Meeting
2017 Genitourinary Cancers Symposium
Early docetaxel-resistance in metastatic hormone-sensitive prostate cancer.
Authors
Nedal Bukhari
University of Western Ontario, London, ON, Canada
Nedal Bukhari , Kylea R. Potvin , D. Scott Ernst , Lori Sax , Eric Winquist
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Prostate Cancer,Urothelial Carcinoma,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 260)
DOI
10.1200/JCO.2017.35.6_suppl.260
Abstract #
260
Poster Bd #
C28
Abstract Disclosures
Similar Posters
Poster
2017 Genitourinary Cancers Symposium
Exploring optimal sequence of abiraterone and enzalutamide in patients with castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.
First Author: Naoki Terada
Poster
2014 Genitourinary Cancers Symposium
Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Antoine Angelergues
Poster
2023 ASCO Annual Meeting
Concurrent chemo-hormonal therapy of enzalutamide (ENZ) and cabazitaxel (CAB) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final analysis of objective response rate (ORR), radiographic progression-free survival (rPFS), and overall survival (OS).
First Author: Alexandra Sokolova
Poster
2023 ASCO Genitourinary Cancers Symposium
Additional cycles of docetaxel in combination with androgen deprivation therapy (D-ADT) in metastatic hormone-sensitive prostate cancer (mHSPC): Efficacy and feasibility analysis.
First Author: Can Aydogdu